Lyophilization Serves as an Effective Strategy for Drug Development of the α9α10 Nicotinic Acetylcholine Receptor Antagonist α-Conotoxin GeXIVA[1,2]
Open Access
- 25 February 2021
- journal article
- research article
- Published by MDPI AG in Marine Drugs
- Vol. 19 (3), 121
- https://doi.org/10.3390/md19030121
Abstract
α-Conotoxin GeXIVA[1,2] is a highly potent and selective antagonist of the α9α10 nicotinic acetylcholine receptor (nAChR) subtype. It has the advantages of strong efficacy, no tolerance, and no effect on motor function, which has been expected help patients with neuropathic pain. However, drug development for clinical use is severely limited owing to its instability. Lyophilization is applied as the most preferred method to solve this problem. The prepared lyophilized powder is characterized by differential scanning calorimetry (DSC), powder X-ray diffractometry (PXRD), and Fourier transform infrared spectroscopy (FTIR). Molecular simulation is also used to explore the internal distribution and forces formed in the system. The analgesic effect on paclitaxel-induced neuropathic pain following single and 14-day repeated administrations are evaluated by the von Frey test and the tail-flick test. Trehalose combined with mannitol in a ratio of 1:1 is employed as the excipients in the determined formulation, where trehalose acts as the stabilizer and mannitol acts as the bulking agent, according to the results of DSC, PXRD, and FTIR. Both GeXIVA[1,2] (API) and GeXIVA[1,2] lyophilized powder (formulation) could produce stable analgesic effect. These results indicated that GeXIVA[1,2] lyophilized powder could improve the stability and provide an effective strategy to push it into clinical use as a new analgesic drug.Keywords
Funding Information
- National Natural Science Foundation of China (81573357)
- National Key Technologies Research and Development Program for New Drugs of China (2018ZX09721003-007, 2018ZX09J18107)
This publication has 58 references indexed in Scilit:
- Effects of alpha 7 positive allosteric modulators in murine inflammatory and chronic neuropathic pain modelsNeuropharmacology, 2013
- Promoted Neuronal Differentiation after Activation of Alpha4/Beta2 Nicotinic Acetylcholine Receptors in Undifferentiated Neural ProgenitorsPLOS ONE, 2012
- Selective knockdown of NMDA receptors in primary afferent neurons decreases pain during phase 2 of the formalin testNeuroscience, 2011
- Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal ResearchPLoS Biology, 2010
- Alpha9 nicotinic acetylcholine receptors and the treatment of painBiochemical Pharmacology, 2009
- Freeze drying of peptide drugs self-associated with long-circulating, biocompatible and biodegradable sterically stabilized phospholipid nanomicellesInternational Journal of Pharmaceutics, 2008
- Opioid-induced HyperalgesiaAnesthesiology, 2006
- α-RgIA: A Novel Conotoxin That Specifically and Potently Blocks the α9α10 nAChR,Biochemistry, 2006
- Molecular mobility of amorphous pharmaceuticals determined using differential scanning calorimetryThermochimica Acta, 2001
- Efficient Analysis of Experimental ObservationsAnnual Review of Pharmacology and Toxicology, 1980